I make a donation

ADRIFT

Searching the rivaroxaban dosis which enables an adequate anticoagulation evaluated by the level of thrombin generated in patients suffering atrial fibrillation and having a successful percutaneous left atrial appendage closure.

Terminée

La Grande Journée du Coeur (13 juin 2023)
Les vidéos sont en ligne !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Endocardite infectieuse" (jeudi 07 novembre 2024)
Réservez vos places !

Remerciements de la Famille COLLET

objectif

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure

date de réalisation

2017

nombre de patients

nombre de centres participants

National multicentric trial

type de financement

Privé (Fonds de Dotation Action & Bayer)

Référence

NCT03273322

A study conducted by Fonds de Dotation ACTION
Find out details and results on the dedicated page

ADRIFT conducted by Fonds de Dotation ACTION

Autres études

ANCHOR

En cours

Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients

AFLOAT

En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.

BIO-TAVI

En cours

Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI